LeonaBio, Inc. 8-K

What Happened LeonaBio, Inc. announced the results of its 2026 Annual Meeting of Stockholders held on June 22, 2026 (filed in an 8-K). There were 9,393,514 shares outstanding as of the record date (May 1, 2026), and 7,908,604 shares (84.19%) were present or represented by proxy. Stockholders elected three Class III directors to terms running until the 2029 annual meeting, ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal 2026, and approved advisory votes on executive compensation and the frequency of those advisory votes.

Key Details

• Shares outstanding (record date May 1, 2026): 9,393,514; shares present/represented: 7,908,604 (84.19%).
• Director elections (votes For / Withhold / Broker Non-Votes):
  • Kelly A. Romano: 4,722,901 For; 630,132 Withhold; 2,555,571 Broker non-votes.
  • James A. Johnson: 5,331,531 For; 21,502 Withhold; 2,555,571 Broker non-votes.
  • Natalie Holles: 5,338,727 For; 14,306 Withhold; 2,555,571 Broker non-votes.
• Ratification of auditor (Ernst & Young LLP): 7,824,681 For; 10,708 Against; 73,215 Abstain.
• Advisory votes on executive compensation:
  • Say-on-pay: 5,310,614 For; 24,139 Against; 18,280 Abstain; 2,555,571 Broker non-votes.
  • Frequency of future advisory votes: plurality for every 3 years — 3,052,542 votes for 3 years (vs. 2,288,358 for 1 year).

Why It Matters The meeting outcomes confirm the Board’s slate of directors and the company’s auditor, providing continuity in governance and financial oversight through at least 2029 and fiscal 2026 audit coverage. The non-binding “say-on-pay” approval and the 3-year frequency choice signal shareholder acceptance of executive compensation practices and set the cadence for future advisory votes (every three years). These governance votes are relevant to investors assessing board stability, oversight, and shareholder alignment with pay practices.